Remove 2016 Remove Physicians Remove Prescription
article thumbnail

Veradigm® Digital Health Media Works to Message the Right Physicians at the Right Time

PM360

As pharma reps’ access to physicians continues to decline, this case study examines the effectiveness of reaching physicians through other means—the EHR. Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. THE CHALLENGE.

article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

Worldwide obesity rates have tripled since 1975, with 650 million adults obese in 2016, according to the World Health Organization. Payers also face hurdles, so patients must obtain permission before filling a prescription. Lamanna anticipates it could take two to three years to change the minds of primary care physicians.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

HeartBeam Announces Acquisition of LIVMOR Assets

Legacy MEDSearch

Founded in 2016, LIVMOR developed the Halo+ Atrial Fibrillation (AF) Detection System, the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. The acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.

article thumbnail

Redesigning Provider Incentives to Influence Practice Patterns and Performance

Clarify Health

1] In a separate, controlled study, 80 percent of primary care physicians receiving micro-incentives referred patients to higher-value specialists they had never used before — representing a significant reduction in the total cost of care. pills per prescription than non-discordant clinicians. million on orthopedic MS-DRGs.[1]

article thumbnail

Drug developers look at innovative mechanisms to tackle dry eye syndrome

Pharmaceutical Technology

Current treatment options for DES are dominated by a mix of prescription and over-the-counter (OTC) products. Competing against Restasis are Novartis’ Xiidra (lifitegrast ophthalmic solution 5%), which launched in the US in 2016, and Sun Pharma’s Cequa (cyclosporine ophthalmic solution 0.09%), which launched in the US in 2019.

article thumbnail

Health consumers: A long way off

World of DTC Marketing

The new healthcare consumer is faced with the challenge of both shopping and saving: shopping for the price of prescription drugs or healthcare services, and saving to pay for deductibles, out-ofpocket costs, and unanticipated medical emergencies. They want to know exactly what they’re getting for their money.

article thumbnail

How Pharmacogenomics may finally realise its promise

pharmaphorum

More than 60 percent of all American adults take prescription drugs , amounting to approximately 131 million individuals. In 2016, the estimated annual cost of drug-related morbidity and mortality resulting from non-optimised medication therapy was $528.4 billion in the United States alone.